Immune checkpoint therapy for non-small-cell lung cancer: an update.
about
The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcomeAntibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Emerging links among Chromosome Instability (CIN), cancer, and aging.Meta-analysis of the risk of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 therapies.PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.[Progress in cancer immunotherapy].Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer.Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.Strategy to targeting the immune resistance and novel therapy in colorectal cancer.Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in TaiwanThe efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysisNeutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancerSoluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemiaPromising clinical application of ctDNA in evaluating immunotherapy efficacyAnti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
P2860
Q29248715-4B0A0373-7A7A-40A0-98E1-D4398AF89295Q33699687-6D9FA503-CAFA-4FCC-8972-1F0821F94300Q37565475-89CBF2EB-E7CD-429C-8F5F-AD921C85DABCQ38899873-B21E864E-F7DD-4FAE-841A-A78C249DC543Q38929880-A06BE343-1A8C-4797-9BA9-CC0D582F6AE7Q39101223-A26BA9BD-74CF-48B0-855B-FAC8ACBB615DQ39452745-EBEBB67E-730C-4A0E-A473-EE0AEC332F9AQ41928232-A0B2CFDA-28E1-4C5A-ADEB-BE99BD39E00CQ48088758-1AFC27AE-F335-40B9-A09B-CC49F849BC38Q49723499-195A9D13-0329-4D34-8B27-C1CC111AE613Q50028797-DACE6C8C-3BAE-48C3-A3D4-A8C8E1D3D00FQ50300666-30B38B09-286E-4632-BB55-6679F07CD7E9Q50634571-C9FFD9C8-6C48-40EA-A2B8-192BBBE7F09DQ52320729-084E4C71-A8BD-4338-8920-F27CFC275212Q57167691-89D9A9F1-1116-4A8B-9F21-F3A7714C3292Q58698737-8A09FFAD-9BB6-4D02-8AB7-D92E282F4F87Q58732737-E52AD782-E952-47AC-B9A1-061CF0183833Q58786066-8031B7D8-8381-4552-BF42-6A463B7E3561Q58790057-68276B3E-D785-4632-AF0A-114FBFF64F65Q58795231-5FAD6956-CDBA-486F-B37B-7D9255953B8D
P2860
Immune checkpoint therapy for non-small-cell lung cancer: an update.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immune checkpoint therapy for non-small-cell lung cancer: an update.
@en
type
label
Immune checkpoint therapy for non-small-cell lung cancer: an update.
@en
prefLabel
Immune checkpoint therapy for non-small-cell lung cancer: an update.
@en
P2860
P356
P1433
P1476
Immune checkpoint therapy for non-small-cell lung cancer: an update.
@en
P2093
P2860
P304
P356
10.2217/IMT.15.123
P577
2016-02-09T00:00:00Z